GlaxoSmithKline has enjoyed a strong start to the year with thanks to a rebound in orders for shingles vaccine Shingrix, big revenues for its COVID-19 antibody therapy Xevudy and strong consumer division growth, among other drivers.
GSK Gets A Lucky Q1 Boost, But All Eyes Are On RSV Vaccine Readout
Revenues Up By 32%
GlaxoSmithKline has just acquired a late-stage oncology asset, and sales of Shingrix are on the up again, but the outcome of its RSV vaccine study remains the main focus for 2022.
